Edition:
United States

Neovasc Inc (NVCN.OQ)

NVCN.OQ on NASDAQ Stock Exchange Capital Market

0.03USD
20 Jul 2018
Change (% chg)

$-0.00 (-4.23%)
Prev Close
$0.04
Open
$0.04
Day's High
$0.04
Day's Low
$0.03
Volume
1,023,453
Avg. Vol
9,830,531
52-wk High
$1.88
52-wk Low
$0.03

Chart for

About

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment... (more)

Overall

Beta: 3.80
Market Cap(Mil.): $82.94
Shares Outstanding(Mil.): 1,860.19
Dividend: --
Yield (%): --

Financials

  NVCN.OQ Industry Sector
P/E (TTM): -- 37.52 33.34
EPS (TTM): -0.75 -- --
ROI: -- 8.76 13.18
ROE: -- 12.58 15.09

BRIEF-Neovasc's Management And Board Of Directors Urge Shareholders To Vote In Favor Of The Proposed Reverse Stock Split

* NEOVASC'S MANAGEMENT AND BOARD OF DIRECTORS URGE SHAREHOLDERS TO VOTE IN FAVOR OF THE PROPOSED REVERSE STOCK SPLIT AT THE UPCOMING ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

May 15 2018

BRIEF-Neovasc Qtrly Operating Losses $6.5 Million

* NEOVASC INC - QTRLY OPERATING LOSSES & COMPREHENSIVE LOSSES WERE $6.5 MILLION & $55.5 MILLION, RESPECTIVELY, OR $0.38 BASIC AND DILUTED LOSS PER SHARE Source text for Eikon: Further company coverage:

May 10 2018

BRIEF-Neovasc Regains Compliance With NASDAQ Minimum Market Value Rule

* NEOVASC REGAINS COMPLIANCE WITH NASDAQ MINIMUM MARKET VALUE RULE Source text for Eikon: Further company coverage:

May 10 2018

BRIEF-Neovasc Receives German Nub Status 1 Designation For Neovasc Reducer Procedure

* NEOVASC ANNOUNCES RECEIPT OF GERMAN NUB STATUS 1 DESIGNATION FOR NEOVASC REDUCER™ PROCEDURE FOR TREATMENT OF REFRACTORY ANGINA Source text for Eikon: Further company coverage:

Feb 01 2018

Earnings vs. Estimates